Target Name: NKX2-5
NCBI ID: G1482
Review Report on NKX2-5 Target / Biomarker Content of Review Report on NKX2-5 Target / Biomarker
NKX2-5
Other Name(s): CHNG5 | homeobox protein NKX 2-5 | NKX4-1 | Homeobox protein Nkx-2.5 | NKX 2-5 | cardiac-specific homeobox 1 | NKX2-5 variant 1 | HLHS2 | Homeobox protein NK-2 homolog E | NKX25_HUMAN | Homeobox protein Nkx-2.5 (isoform 1) | NK2 transcription factor related, locus 5 | NK2 homeobox 5 | CSX | CSX1 | tinman homolog | tinman paralog | homeobox protein NK-2 homolog E | VSD3 | NK2 homeobox 5, transcript variant 1 | NKX2E | NKX2.5 | homeobox protein CSX | Homeobox protein CSX | Cardiac-specific homeobox

Unlocking The Potential of NKX2-5: A Non-Coding RNA Molecule as A Drug Target Or Biomarker

NKX2-5, also known as CHNG5, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and functional implications have piqued the interest of researchers in the field of neuroscience, immunology, and regenerative medicine.

The NKX2-5 molecule is a non-coding RNA molecule that is expressed in various tissues and cell types in the body. It is characterized by its unique structure, which consists of a long stem-loop region and a series of variable and constant regions at its ends. The stem-loop region is the most conserved part of the molecule and is responsible for the formation of a stem-loop structure.

One of the unique features of NKX2-5 is its ability to interact with various protein molecules, including transcription factors. This interaction between NKX2-5 and transcription factors has led to the conclusion that NKX2-5 plays a role in the regulation of gene expression . Additionally, NKX2-5 has been shown to interact with the protein PDGF-BB, which is a known regulator of cell proliferation and survival.

The functional implications of NKX2-5 are significant. Its ability to interact with transcription factors and other proteins suggests that it may be a potential drug target or biomarker for various diseases. The fact that NKX2-5 is also expressed in various tissues and cell types also increases its potential as a biomarker.

In cancer, NKX2-5 has been shown to be involved in the regulation of cell proliferation and survival. Several studies have shown that high levels of NKX2-5 are associated with poor prognosis in cancer patients. Additionally, NKX2-5 has been shown to be involved in the development of various types of cancer, including neuroendocrine, lung, and kidney cancer.

In addition to its potential as a drug target or biomarker, NKX2-5 also has implications for regenerative medicine. Its ability to interact with transcription factors suggests that it may be involved in the regulation of stem cell proliferation and differentiation. This suggests that NKX2- 5 may be a useful tool for the development of regenerative treatments for various diseases.

Overall, NKX2-5 is a non-coding RNA molecule that exhibits unique characteristics and has been shown to be a potential drug target or biomarker in a variety of diseases, including cancer. Its special structural biological characteristics and functional characteristics of interactions with proteins have attracted the attention of researchers. In the future, further research will reveal the potential role of NKX2-5 in drug discovery and treatment of cancer.

Protein Name: NK2 Homeobox 5

Functions: Transcription factor required for the development of the heart and the spleen (PubMed:22560297). During heart development, acts as a transcriptional activator of NPPA/ANF in cooperation with GATA4 (By similarity). May cooperate with TBX2 to negatively modulate expression of NPPA/ANF in the atrioventricular canal (By similarity). Binds to the core DNA motif of NPPA promoter (PubMed:22849347, PubMed:26926761). Together with PBX1, required for spleen development through a mechanism that involves CDKN2B repression (PubMed:22560297). Positively regulates transcription of genes such as COL3A1 and MMP2, resulting in increased pulmonary endothelial fibrosis in response to hypoxia (PubMed:29899023)

The "NKX2-5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NKX2-5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

NKX2-6 | NKX2-8 | NKX3-1 | NKX3-2 | NKX6-1 | NKX6-2 | NKX6-3 | NLE1 | NLGN1 | NLGN1-AS1 | NLGN2 | NLGN3 | NLGN4X | NLGN4Y | NLK | NLN | NLRC3 | NLRC4 | NLRC4 Inflammasome | NLRC5 | NLRP1 | NLRP1 Inflammasome | NLRP10 | NLRP11 | NLRP12 | NLRP13 | NLRP14 | NLRP2 | NLRP2B | NLRP3 | NLRP3 Inflammasome | NLRP3P1 | NLRP4 | NLRP5 | NLRP6 | NLRP7 | NLRP8 | NLRP9 | NLRP9P1 | NLRX1 | NMB | NMBR | NMD3 | NMDA receptor | NME1 | NME1-NME2 | NME2 | NME2P1 | NME3 | NME4 | NME5 | NME6 | NME7 | NME8 | NME9 | NMI | NMNAT1 | NMNAT2 | NMNAT3 | NMRAL1 | NMRAL2P | NMRK1 | NMRK2 | NMS | NMT1 | NMT2 | NMTRQ-TTG10-1 | NMTRQ-TTG12-1 | NMTRV-TAC1-1 | NMU | NMUR1 | NMUR2 | NNAT | NNMT | NNT | NNT-AS1 | NOA1 | NOB1 | NOBOX | NOC2L | NOC2LP2 | NOC3L | NOC4L | NOCT | NOD1 | NOD2 | NODAL | NOG | NOL10 | NOL11 | NOL12 | NOL3 | NOL4 | NOL4L | NOL4L-DT | NOL6 | NOL7 | NOL8 | NOL9 | NOLC1